Neuraxis, Inc. NRXS

NeurAxis announces a medical coverage policy milestone expanding access to over 18 million additional covered lives. Coverage expansion to 18 million more lives significantly boosts NeurAxis revenue potential and market reach.

Neuraxis Inc. (NRXS) stock rose nearly 137% over the past year on the back of factors supporting its performance. Year-long 137% stock advance points to major positive developments that can reshape trajectory and sentiment.

Neuraxis Inc (NRXS) posted a 116% revenue surge in Q2 2026 driven by expanded payer coverage. 116% revenue growth combined with payer coverage gains signals major positive shifts in financial trajectory and market position.

NeurAxis, Inc. reported record second quarter 2026 financial results driven by 116% year-over-year revenue growth. Record revenue surge points to stronger financial trajectory and investor interest.

NeurAxis, Inc. held its Q2 2026 earnings call covering financial results, operations, and outlook. Quarterly earnings call delivers updates on results and strategy with moderate effects on near-term stock movement.

NeurAxis, Inc. expands payer coverage with new policies. New payer policies broaden insurance coverage and support higher revenue potential for NeurAxis.

NeurAxis (NRXS) stock rises on progress with reimbursement approvals and supportive clinical guideline updates that expand access to its neuromodulation therapies. Reimbursement wins and guideline inclusion directly boost revenue access and adoption for NeurAxis core therapies.

NeurAxis, Inc. (NRXS) stock rose after Q1 earnings showed year-over-year surges in revenues and margins. Q1 revenue and margin surges year-over-year drove stock gains, indicating significant positive momentum in financial performance.

NeurAxis, Inc. held its Q1 2026 earnings call covering financial results and business updates. Earnings details can moderately shift near-term investor views and operational expectations.

Neuraxis Inc. (NRXS) Q1 2026 earnings call highlighted strong revenue growth despite ongoing coverage challenges. Strong revenue growth signals significant positive shift in financial performance and investor sentiment for NRXS despite coverage obstacles.

NeurAxis, Inc. (NRXS) announced record first quarter 2026 financial results, driven by 80% year-over-year revenue growth. 80% YoY revenue growth marks a significant boost to financial performance and investor sentiment.

NeurAxis, Inc. (NRXS) expands payer coverage with four new medical policies, enhancing reimbursement access for its neuromodulation therapy. Four new payer policies expand reimbursement access, driving revenue growth and accelerating product adoption for NeurAxis.

NeurAxis, Inc. (NRXS) stock gained after Q4 earnings report highlighted strong revenue growth. Strong Q4 revenue growth triggered stock gains, signaling major positive shift in financial performance and investor sentiment.

NeurAxis, Inc. (NRXS) released Q4 2025 earnings call summary detailing financial results, operational updates, and forward-looking guidance. Q4 earnings summary highlights annual financial performance and strategic initiatives with potential to significantly influence investor sentiment and stock trajectory.

NeurAxis, Inc. (NRXS) reported strong fourth quarter and full year 2025 financial results. Strong financial results enhance revenue growth, profitability outlook, and investor sentiment for future performance.

Neuraxis Inc (NRXS) Q4 2025 earnings call highlights revenue growth despite operational challenges. Revenue growth boosts financials but operational challenges limit broader trajectory shifts.

Neuraxis, Inc. has achieved a significant milestone with the implementation of a Category I CPT® code by the American Medical Association, establishing a permanent reimbursement pathway for its services. This development is expected to enhance the company's financial stability and facilitate broader access to its innovative treatments, potentially leading to increased adoption and market growth. The establishment of a permanent reimbursement pathway is likely to significantly impact Neuraxis's future performance and investor sentiment.

Neuraxis, Inc. has achieved a significant milestone by securing a medical coverage policy that expands access to its services for approximately 45 million additional covered lives. This development is expected to enhance patient access to Neuraxis's innovative treatments, potentially increasing the company's market reach and revenue opportunities. The expansion of medical coverage to 45 million additional lives is likely to significantly impact Neuraxis's market performance and growth trajectory.

Neuraxis, Inc. has secured a Federal Supply Schedule contract with Veterans Affairs, which will enhance access to its treatment for patients suffering from functional abdominal pain. This contract is expected to facilitate broader distribution of Neuraxis's solutions within the veteran community, potentially improving patient outcomes and expanding the company's market reach. Securing a Federal Supply Schedule contract is a significant strategic move that can enhance market access and patient reach for Neuraxis.

Neuraxis, Inc. (NRXS) has announced new medical policy coverage in Michigan, which will benefit approximately 566,000 covered lives. This expansion is expected to enhance access to their services and potentially increase the company's market presence in the region. The new medical policy coverage significantly expands access to Neuraxis's services, likely impacting future performance and investor sentiment positively.

Neuraxis, Inc. (NRXS) reported strong financial results for the third quarter of 2025, showcasing a 22% increase in revenues compared to the previous year. This growth reflects the company's successful strategies and market positioning, contributing positively to its overall financial health. The significant revenue growth indicates a strong market position and potential for future expansion.

Neuraxis, Inc. has received FDA clearance for its innovative treatment targeting pain associated with Functional Dyspepsia (FD) and nausea symptoms in adults. This marks a significant milestone as it is the first FDA approval for this specific condition, potentially expanding treatment options for patients suffering from FD. FDA clearance for a novel treatment represents a significant advancement in addressing a previously underserved medical condition.

Neuraxis, Inc. (NRXS) reported strong financial results for the second quarter of 2025, showcasing a 46% increase in revenues compared to the previous year. This growth reflects the company's successful strategies and market positioning, contributing positively to its overall financial health. The significant revenue growth indicates a strong market position and potential for future expansion.

Neuraxis, Inc. (NRXS) will host a call on August 12, 2025, to discuss its second quarter 2025 results and provide a business update. This event is expected to offer insights into the company's financial performance and strategic direction. The scheduled call may provide important updates that could moderately influence investor sentiment and financial performance.

NeurAxis, Inc. (NRXS) has seen a 10.2% increase in shares year-to-date, compared to an 18% gain in the Zacks Medical Info Systems industry. The company targets the $8 billion pediatric gut-brain disorder market with its FDA-cleared IB-Stim therapy, which has expanded its market potential significantly. The recent label expansion increased covered lives from 4 million to 53 million, and a new CPT code is expected to enhance physician adoption. However, risks include high cash burn and slow CPT implementation. Despite these challenges, strong intellectual property and a first-mover advantage in a $22 billion market support long-term growth prospects. The recent label expansion and new CPT code are likely to significantly enhance NeurAxis's market position and revenue potential.

NeurAxis, Inc. (NRXS) has seen a 10.2% increase in shares year-to-date, compared to the 18% gain in the Zacks Medical Info Systems industry. The company targets the $8 billion pediatric gut-brain disorder market with its FDA-cleared IB-Stim therapy, which has expanded its market potential significantly. The recent label expansion increased covered lives from 4 million to 53 million, and a permanent CPT code is expected to enhance physician adoption. Additionally, the clearance of the RED device opens a $2 billion adult diagnostic market. However, risks include high cash burn and slow CPT implementation. The recent label expansion and new market opportunities could significantly alter NeurAxis's growth trajectory and investor sentiment.

Neuraxis, Inc. (NRXS) has announced new medical policy coverage agreements with two health insurers, which will extend coverage to an additional 700,000 lives. This expansion is expected to enhance patient access to Neuraxis's services and potentially increase the company's market presence. The new coverage agreements significantly expand patient access, likely impacting future revenue and market positioning.

NeurAxis, Inc. announced that its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology has been included in new clinical practice guidelines for treating Functional Abdominal Pain (FAP) in Irritable Bowel Syndrome (IBS) in children. This recognition is expected to enhance insurance coverage for its product, IB-Stim, and drive growth in a market estimated at over $3 billion in the U.S. The guidelines, developed by leading pediatric gastroenterology societies, highlight PENFS as one of the top therapies based on evidence. NeurAxis aims to address the needs of over 600,000 children suffering from FAP in the U.S. Inclusion in clinical guidelines is likely to significantly enhance market adoption and insurance coverage for IB-Stim, impacting future revenue and growth.

NeurAxis, Inc. will participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025, hosting a webcast presentation at 9:30 a.m. ET and one-on-one meetings with investors. The webcast can be accessed online and will be available for replay. NeurAxis focuses on neuromodulation therapies for chronic conditions, with its IB-Stim™ therapy FDA cleared for treating functional abdominal pain associated with IBS in adolescents. The company is also conducting additional clinical trials for various conditions. Participation in investor conferences can enhance visibility and investor interest, potentially affecting market sentiment and financial performance.

Neuraxis, Inc. (NRXS) has successfully closed a registered direct offering, raising $5.0 million. The offering involved the sale of shares at a price of $0.50 each, with the company planning to use the proceeds for general corporate purposes, including working capital and potential future acquisitions. The transaction is expected to enhance the company's financial position and support its strategic initiatives. The capital raised will provide Neuraxis with additional resources to support its operations and strategic goals.